Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (10): 1001-1005.doi: 10.3969/j.issn.1000-6621.2021.10.005
• Original Articles • Previous Articles Next Articles
YING Ruo-yan, HUANG Xiao-chen, WANG Jie, LIU Yi-dian, SHA Wei, YANG Hua()
Received:
2021-04-27
Online:
2021-10-10
Published:
2021-10-11
Contact:
YANG Hua
E-mail:yanghua97065@163.com
YING Ruo-yan, HUANG Xiao-chen, WANG Jie, LIU Yi-dian, SHA Wei, YANG Hua. Analysis of the correlation between sensitivity of drugs in the treatment and the outcome of treatment in pulmonary tuberculosis patients retreated for the first time[J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1001-1005. doi: 10.3969/j.issn.1000-6621.2021.10.005
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.10.005
[1] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[2] |
Cohen DB, Davies G, Malwafu W, et al. Poor outcomes in recurrent tuberculosis: More than just drug resistance? PLoS One, 2019, 14(5): e0215855. doi: 10.1371/journal.pone.0215855.
doi: 10.1371/journal.pone.0215855 URL |
[3] |
Cohen DB, Meghji J, Squire SB. A systematic review of clinical outcomes on the WHO Category Ⅱ retreatment regimen for tuberculosis. Int J Tuberc Lung Dis, 2018, 22(10): 1127-1134. doi: 10.5588/ijtld.17.0705.
doi: 10.5588/ijtld.17.0705 pmid: 30236179 |
[4] |
沙巍, 张青, 崔文玉, 等. 首次复治肺结核患者短程化疗新方案的临床研究. 中国防痨杂志, 2017, 39(1): 39-45. doi: 10.3969/j.issn.1000-6621.2017.01.011.
doi: 10.3969/j.issn.1000-6621.2017.01.011 |
[5] |
Yan L, Kan X, Zhu L, et al. Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China. Clin Ther, 2018, 40(3): 440-449. doi: 10.1016/j.clinthera.2018.01.013.
doi: 10.1016/j.clinthera.2018.01.013 URL |
[6] |
Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005, 26(4): 292-297. doi: 10.1016/j.ijantimicag.2005.05.005.
doi: 10.1016/j.ijantimicag.2005.05.005 URL |
[7] |
应若嫣, 黄晓辰, 王洁, 等. 耐药MTB分离株对不同组合抗结核药品体外药物敏感性试验的结果分析. 中国防痨杂志, 2020, 42(11): 1183-1190. doi: 10.3969/j.issn.1000-6621.2020.11.008.
doi: 10.3969/j.issn.1000-6621.2020.11.008 |
[8] |
Rey-Jurado E, Tudó G, de la Bellacasa JP, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents, 2013, 41(3): 278-280. doi: 10.1016/j.ijantimicag.2012.11.011.
doi: 10.1016/j.ijantimicag.2012.11.011 URL |
[9] |
闫丽萍, 吴哲渊, 张祖荣, 等. 初治耐多药肺结核患者采用初治标准方案治疗的前瞻性临床研究. 中国防痨杂志, 2017, 39(1): 33-38. doi: 10.3969/j.issn.1000-6621.2017.01.010.
doi: 10.3969/j.issn.1000-6621.2017.01.010 |
[10] |
Daley CL, Caminero JA. Management of Multidrug-Resistant Tuberculosis. Semin Respir Crit Care Med, 2018, 39(3): 310-324. doi: 10.1055/s-0038-1661383.
doi: 10.1055/s-0038-1661383 URL |
[11] |
Saravia JC, Appleton SC, Rich ML, et al. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis, 2005, 9(4): 421-429.
pmid: 15830748 |
[12] |
Gegia M, Winters N, Benedetti A, et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis, 2017, 17(2): 223-234. doi: 10.1016/S1473-3099(16)30407-8.
doi: 10.1016/S1473-3099(16)30407-8 URL |
[13] |
Rothstein DM. Rifamycins, Alone and in Combination. Cold Spring Harb Perspect Med, 2016, 6(7): a027011. doi: 10.1101/cshperspect.a027011.
doi: 10.1101/cshperspect.a027011 URL |
[14] |
Temple ME, Nahata MC. Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother, 1999, 33(11): 1203-1210. doi: 10.1345/aph.18450.
doi: 10.1345/aph.18450 pmid: 10573321 |
[15] | Zheng XM, Li SM, Xing BC. Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi-drug resistant pulmonary tuberculosis. Di Yi Jun Yi Da Xue Xue Bao, 2004, 24(5): 574-575, 578. |
[16] |
Wernsdorfer G, Wernsdorfer WH. Antituberculosis treatment with pasiniazide (isoniazide p-aminosalicylate): experimental and clinical aspects. Maroc Med, 1970, 50(533): 164-168.
pmid: 5517526 |
[17] |
Gillespie SH. The role of moxifloxacin in tuberculosis therapy. Eur Respir Rev, 2016, 25(139): 19-28. doi: 10.1183/16000617.0085-2015.
doi: 10.1183/16000617.0085-2015 pmid: 26929417 |
[18] |
Naidoo A, Chirehwa M, Mcilleron H, et al. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. J Antimicrob Chemother, 2017, 72(5): 1441-1449. doi: 10.1093/jac/dkx004.
doi: 10.1093/jac/dkx004 URL |
[1] | YU Xia, REN Ru-yan, WEN Shu-an, LIANG Qian, DONG Ling-ling, HUANG Hai-rong. Evaluation of in vitro antibacterial effects of 13 antibiotics against rapidly growing mycobacteria [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 947-951. |
[2] | YI Jun-li, YANG Xin-yu, CHEN Hao, ZHAO Yan-feng, CHEN Shuang-shuang, ZHANG Jie, DING Bei-chuan, DAI Xiao-wei, SUN Shan-hua, WU Wen-qing, LI Chuan-you. Analysis of drug resistance of 1156 clinical isolates of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 677-681. |
[3] | FAN Jun, ZHANG Wen, ZHANG Ting, WANG Qing-ya, YU Ya, CHENG Jun. Analysis on characteristics of reported pulmonary tuberculosis among students in Chongqing from 2008 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 716-723. |
[4] | WANG Lu, XUE Zhong-tan, WANG Yu-feng, SHANG Yuan-yuan, REN Wei-cong, YAO Cong, GAO Fei, PANG Yu. A study of dynamic monitoring of drug sensitivity of Mycobacterium tuberculosis to bedaquiline and the mechanism of drug resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 482-486. |
[5] | FENG Bin-bin, JIN Feng, JING Hui, WANG Jun-ling, LIN Mei-ying, QIAO Xiu-li, LI Ming, QIU Li-hua. Identification and drug resistance of 439 clinical isolates of non-tuberculosis mycobacterium in Shandong [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 516-520. |
[6] | MA Yan*, GAO Wei-wei. Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317. |
[7] | SHU Wei, GE Qi-ping, HUANG Xue-rui, MA Li-ping, JI Bin-ying, CHEN Yu-hui, CHEN Xiao-you, JIANG Guang-lu, XIE Li, LI Bo, CHEN Sheng-yu, CHEN Sen-lin, YAN Jun-ping, SHI Lian, CHEN Ling, LI You-lun, XI Xiu-e, LIU Qian-ying, YAN Xing-lu, WANG Fei, WANG Fu-rong, WU Xiang, ZHANG Peng, LENG Xue-yan, CAO Wen-li, ZHANG Hai-qing, CUI Hong-zhe, YANG Cheng-qing, WU Chao, LI Juan, LI Hua, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, NING Yu-jia, TIAN Xi-zhong, DU Jian, LI Liang, GAO Wei-wei. Analysis of treatment outcomes of retreated pulmonary tuberculosis patients with isoniazid-resistance and rifampin-resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 322-327. |
[8] | GE Qi-ping*, DU Jian, SHU Wei, MA Yan, MA Li-ping, ZHAO Cai-yan, CHEN Yu-hui, ZHANG Li-jie, HUANG Xue-rui, HAN Xi-qin, CHEN Sheng-yu, WANG Fei, LI Bo, CAO Wen-li, LIU Qian-ying, CHEN Dong-jin, SHI Lian, WANG Xin, LI You-lun, YANG Shang-peng, PENG Zhang-li, WU Chao, OUYANG Bing, WANG Fu-rong, LI Po, WU Xiang, XI Xiu-e, LENG Xue-yan, ZHANG Hai-qing, LI Hua, LI Juan, YANG Cheng-qing, ZHANG Peng, CUI Hong-zhe, XIE Li, LIU Yu-hong, LI Liang, GAO Wei-wei. Treatment effect analysis of the optimized regimen for re-treated drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 328-334. |
[9] | ZHANG Li-jie*, HAN Xi-qin, WANG Jing-ping, CHEN Yu-hui, CHEN Sheng-yu, CHEN Ling, LI Bo, LIN Ming-gui, LI You-lun, SHI Lian, XI Xiu-e, MA Li-ping, WANG Xin, WANG Fei, ZHAO Cai-yan, WANG Fu-rong, CHEN Sen-lin, WU Xiang, LI Po, ZHANG Peng, LENG Xue-yan, ZHANG Hai-qing, CAO Wen-li, SHU Wei, SUN Yu-xian, XIE Shi-heng, TIAN Xi-zhong, HUANG Xue-rui, DU Jian, GAO Wei-wei. The relationship between bacterial load and treatment failure and recurrence of sputum positive retreatment pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 335-340. |
[10] | WANG Xi-jiang, TAN Yun-hong, HE Wen-cong, OU Xi-chao, LIU Dong-xin, ZHAO Yan-lin. The correlation between rifampicin and isoniazid resistance-related gene mutations and resistance level in Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(3): 248-254. |
[11] | LI Yuan-chun, ZHANG Yue, ZENG Xiang-jie, HE Wen-cong, QIU Qian, ZHAO Yan-lin, LI Yan-ming. Subspecies and in vitro drug sensitivity analysis of Mycobacterium intracellular clinical isolates [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 147-152. |
[12] | CHENG Wu, TAN Shou-yong, LI Yan, LI Qiong. Clinical characteristics of retreated bacterial negative pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1006-1009. |
[13] | LIU Zhi-bin, WU Min, WU Xiao-cui, HAN Min, ZHANG Qing, SHA Wei. Individualized treatment for retreatment smear-positive pulmonary tuberculosis patients based on molecular drug susceptibility testing and its short-term effectiveness [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1010-1015. |
[14] | LIU Zhi-bin, WU Min, WU Xiao-cui, HAN Min, XIAO He-ping, ZHANG Qing. The value of PCR-reverse dot blot hybridization in detecting the drug resistance of Mycobacterium tuberculosis in sputum specimens of retreatment smear-positive pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 47-51. |
[15] | LI Qian, WANG Lin-bao, LUO Pei-jia, WEI Lin, LIU Yu-gang, REN Lei-peng, DING Chao. Analysis of the results of etiology and drug resistance in different surgical specimens of tuberculous empyema by two techniques [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 52-57. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||